US HB6179 | 2019-2020 | 116th Congress
Status
Spectrum: Bipartisan Bill
Status: Introduced on March 10 2020 - 25% progression, died in committee
Action: 2020-03-10 - Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Pending: House Energy And Commerce Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on March 10 2020 - 25% progression, died in committee
Action: 2020-03-10 - Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Pending: House Energy And Commerce Committee
Text: Latest bill text (Introduced) [PDF]
Summary
Requires the Centers for Medicare & Medicaid Services to establish a demonstration project to evaluate the benefits of providing additional payments to providers of biosimilars under Medicare. Specifically, under the demonstration project, participating providers receive an additional payment based on the difference between the costs to the provider of furnishing the biosimilar and the cost if the provider had furnished the underlying reference biological product instead.
Title
Increasing Access to Biosimilars Act of 2020
Sponsors
| Rep. Tony Cardenas [D-CA] | Rep. Richard Hudson [R-NC] | Rep. Angela Craig [D-MN] | Rep. Brian Fitzpatrick [R-PA] |
| Rep. Gus Bilirakis [R-FL] | Rep. Lisa Rochester [D-DE] | Rep. David McKinley [R-WV] |
History
| Date | Chamber | Action |
|---|---|---|
| 2020-03-10 | House | Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. |
| 2020-03-10 | House | Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. |
| 2020-03-10 | House | Introduced in House |
Same As/Similar To
SB4134 (Related) 2020-07-01 - Read twice and referred to the Committee on Finance.
Subjects
Congressional oversight
Government studies and investigations
Health
Health care costs and insurance
Medicare
Prescription drugs
Government studies and investigations
Health
Health care costs and insurance
Medicare
Prescription drugs
US Congress State Sources
| Type | Source |
|---|---|
| Summary | https://www.congress.gov/bill/116th-congress/house-bill/6179/all-info |
| Text | https://www.congress.gov/116/bills/hr6179/BILLS-116hr6179ih.pdf |
